OGN
Organon & Co.
Next earnings Aug 3, 2026 · consensus $0.93 EPS, $1.58B rev
Last earnings -0.7% on 2026-04-30
$13.50
▲ +0.22%$13.50▲ +39.68%
over 1Y
L $5.69EODHDH $13.50
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.2%
1W+0.7%
1M+0.9%
3M+131.5%
YTD+87.2%
1Y+39.7%
Sell
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 13 analysts
Sell
OGN looks cheap at 0.6x sales but earnings collapsed 78%, Nexplanon LOE hits 2027, and $8.6B debt leaves no margin for error.
Revenue $6.22B · FY2025
The read
Weak on both the fundamentals and the price — little to like at the current level.
OGN screens optically cheap (P/S 0.6, P/E 18.7, P/E on collapsed earnings is misleading) but the fundamentals are deteriorating fast. FY2025 revenue fell 2.9% to $6.22B and net income collapsed 78.4% from $864M to $187M, dragging diluted EPS from a prior trajectory to just $0.72. Net margin compressed to 3.0% and gross profit fell 10.8% even as revenue only slipped 2.9% — a tell that pricing/mix is breaking down, not just volume. The 10-K confirms the cause: roughly $197M of LOE impact in 2025 (Atozet in France/Spain/Japan, Rosuzet in Japan), Singulair price reductions in China/Japan, Dulera losing a US customer contract, and continued China VBP pressure expected for several more quarters.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $6.30B | $6.17B | $6.26B | $6.40B | $6.22B |
| Gross profit | — | $3.88B | $3.75B | $3.71B | $3.31B |
| Operating income | — | — | — | — | — |
| Net income | $1.35B | $917M | $1.02B | $864M | $187M |
| Diluted EPS | $5.31 | $3.59 | $3.99 | $3.33 | $0.72 |
| Net margin | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$11.6B
EV / EBITDA—
EV / Sales1.9
EV / FCF21.5
P / FCF6.5
PEG (trailing)—
Earnings yield5.3%
FCF yield15.3%
Quality & risk
ROIC (est.)—
Free cash flow$538M
Total debt$8.64B
Net cash-$8.07B
Piotroski F-Score5/9
Capital returns
Buyback yield—
Dividend yield (est.)2.5%
Shareholder yield2.5%
Shares Δ YoY+0.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K Officer / director change2026-06-11
Annual meeting vote results plus board/officer change disclosed
- 10-Q Quarterly report2026-05-04
Q1 2026 10-Q filed; Jada divestiture to Laborie for up to $465M closed
- 8-K Earnings results2026-04-30
Q1 2026 earnings release issued amid ongoing LOE and tariff pressures
- 8-K Officer / director change2026-04-27
New material agreement signed alongside officer transition and Reg FD update
- DEF 14A Proxy statement2026-04-24
2026 proxy outlines pay and board slate amid material-weakness remediation
- 10-K Annual report2026-02-24
FY2025 10-K: EPS $0.72 (-78%), Atozet LOE, unremediated material weaknesses
- 8-K Other event2026-02-20
Other-event disclosure following 2025 results and restatement work
- 8-K Earnings results2026-02-12
FY2025 earnings: revenue -3%, net income collapsed 78% to $187M
- 8-K Earnings results2025-11-10
FY2024 10-K/A restates results and discloses material weaknesses
Recent filings
all on EDGAR ↗DEFM14AFiling2026-06-17open ↗4Period ending 2026-06-122026-06-15open ↗4Period ending 2026-06-122026-06-15open ↗4Period ending 2026-06-122026-06-15open ↗4Period ending 2026-06-122026-06-15open ↗4Period ending 2026-06-122026-06-15open ↗4Period ending 2026-06-122026-06-15open ↗4Period ending 2026-06-122026-06-15open ↗4Period ending 2026-06-122026-06-15open ↗4Period ending 2026-06-122026-06-15open ↗8-KPeriod ending 2026-06-092026-06-11open ↗DEFA14AFiling2026-06-11open ↗
Frequently asked
- Is Organon & Co. (OGN) a buy?
- OGN currently carries a Sell rating with 4/5 conviction, derived from its latest SEC filings. OGN looks cheap at 0.6x sales but earnings collapsed 78%, Nexplanon LOE hits 2027, and $8.6B debt leaves no margin for error.
- What is OGN's fair value?
- A Modified-Graham model based on OGN's SEC fundamentals estimates a fair value of about $5.76. It is an estimate from reported earnings, not a price target.
- Is OGN overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, OGN currently appears overvalued relative to its SEC-grounded earnings power.
- What is Organon & Co.'s quality score?
- OGN scores 60.59803921568627/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001821825, latest 10-Q filed 2026-05-04) · EODHD · analysis by claude-code · as of 6/25/2026, 1:27:30 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.